Pharmaceuticals

Repairing the Spine: Q&A with NervGen CEO Mike Kelly

bexib
By bexib 0 Min Read

Kelly explains how the company is taking a different approach to spinal cord injuries.

You Might Also Like

AMBLor prognostic melanoma biomarker receives UKCA mark

European Association for Medical Education AMEE 2024 Conference

Improving the U.S. supply chain to improve patient outcomes

HDR UK and DPUK award £2 million to new Motor Neurone Disease research initiative

FDA approves Medtronic’s Simplera continuous glucose monitor; Abbott announces collaboration

Share This Article
Previous Article TD is accepting applications for the 2024 TD Ready Challenge
Next Article Fintech funding: North American companies dominate first half investment
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

New e -commerce tool: January 30, 2025
Retail & E-commerce
Promote the economic collaboration for 2025 business tournaments in Italy and India
Manufacturing
How to create print on demand products
Retail & E-commerce
Is this episode a deep fake? -What is a brewing podcast (episode 9)
Insurance